{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T16:00:17Z","timestamp":1693584017285},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T00:00:00Z","timestamp":1594944000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T00:00:00Z","timestamp":1594944000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Pfizer Inc"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1007\/s40121-020-00322-5","type":"journal-article","created":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T16:50:50Z","timestamp":1595004650000},"page":"625-639","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Sex, Age, and Race Effects on Immunogenicity of MenB-FHbp, A Bivalent Meningococcal B Vaccine: Pooled Evaluation of Clinical Trial Data"],"prefix":"10.1007","volume":"9","author":[{"given":"Johannes","family":"Beeslaar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Peyrani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith","family":"Absalon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Maguire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Eiden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Balmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger","family":"Maansson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John L.","family":"Perez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,17]]},"reference":[{"key":"322_CR1","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.jadohealth.2016.03.041","volume":"59","author":"F Martin\u00f3n-Torres","year":"2016","unstructured":"Martin\u00f3n-Torres F. Deciphering the burden of meningococcal disease: conventional and under-recognized elements. J Adolesc Health. 2016;59:S12\u201320.","journal-title":"J Adolesc Health"},{"key":"322_CR2","unstructured":"Centers for Disease Control and Prevention. Enhanced meningococcal disease surveillance report (2017). https:\/\/www.cdc.gov\/meningococcal\/downloads\/NCIRD-EMS-Report-2017.pdf."},{"key":"322_CR3","unstructured":"European Centre for Disease Prevention and Control. Surveillance Atlas of Infectious Diseases (2019). https:\/\/ecdc.europa.eu\/en\/surveillance-atlas-infectious-diseases. Accessed 3 June 2019."},{"key":"322_CR4","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/2515135518781757","volume":"6","author":"P Balmer","year":"2018","unstructured":"Balmer P, York LJ. Optimal use of meningococcal serogroup B vaccines: moving beyond outbreak control. Ther Adv Vaccines Immunother. 2018;6:49\u201360.","journal-title":"Ther Adv Vaccines Immunother."},{"key":"322_CR5","unstructured":"Trumenba\u00ae (meningococcal group B vaccine). Full Prescribing Information, Wyeth Pharmaceuticals Inc (a subsidiary of Pfizer Inc), Philadelphia; 2018."},{"key":"322_CR6","unstructured":"Bexsero\u00ae (meningococcal group B vaccine). Full Prescribing Information, GSK Vaccines, Srl, Siena; 2018."},{"key":"322_CR7","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1086\/600141","volume":"200","author":"E Murphy","year":"2009","unstructured":"Murphy E, Andrew L, Lee KL, et al. Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J Infect Dis. 2009;200:379\u201389.","journal-title":"J Infect Dis"},{"key":"322_CR8","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1056\/NEJMoa1614474","volume":"347","author":"L Ostergaard","year":"2017","unstructured":"Ostergaard L, Vesikari T, Absalon J, et al. A bivalent meningococcal B vaccine in adolescents and young adults. N Engl J Med. 2017;347:2349\u201362.","journal-title":"N Engl J Med"},{"key":"322_CR9","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1080\/14760584.2018.1483726","volume":"17","author":"JL Perez","year":"2018","unstructured":"Perez JL, Absalon J, Beeslaar J, et al. From research to licensure and beyond: clinical development of MenB-FHbp, a broadly protective meningococcal B vaccine. Expert Rev Vaccines. 2018;17:461\u201377.","journal-title":"Expert Rev Vaccines."},{"key":"322_CR10","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.4161\/hv.24696","volume":"9","author":"JM Lord","year":"2013","unstructured":"Lord JM. The effect of ageing of the immune system on vaccination responses. Hum Vaccines Immunother. 2013;9:1364\u20137.","journal-title":"Hum Vaccines Immunother."},{"key":"322_CR11","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/eji.200838620","volume":"39","author":"A Demirjian","year":"2009","unstructured":"Demirjian A, Levy O. Safety and efficacy of neonatal vaccination. Eur J Immunol. 2009;39:36\u201346.","journal-title":"Eur J Immunol"},{"key":"322_CR12","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1093\/cid\/civ686","volume":"61","author":"CH van Werkhoven","year":"2015","unstructured":"van Werkhoven CH, Huijts SM, Bolkenbaas M, Grobbee DE, Bonten MJ. The impact of age on the efficacy of 13-valent pneumococcal conjugate vaccine in elderly. Clin Infect Dis. 2015;61:1835\u20138.","journal-title":"Clin Infect Dis"},{"key":"322_CR13","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1093\/infdis\/jis619","volume":"207","author":"PS Sow","year":"2013","unstructured":"Sow PS, Watson-Jones D, Kiviat N, et al. Safety and immunogenicity of human papillomavirus-16\/18 AS04-adjuvanted vaccine: a randomized trial in 10-25-year-old HIV-seronegative African girls and young women. J Infect Dis. 2013;207:1753\u201363.","journal-title":"J Infect Dis"},{"key":"322_CR14","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.jadohealth.2007.02.015","volume":"40","author":"C Pedersen","year":"2007","unstructured":"Pedersen C, Petaja T, Strauss G, et al. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health. 2007;40:564\u201371.","journal-title":"J Adolesc Health"},{"key":"322_CR15","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1146\/annurev-cellbio-100616-060718","volume":"33","author":"KL Flanagan","year":"2017","unstructured":"Flanagan KL, Fink AL, Plebanski M, Klein SL. Sex and gender differences in the outcomes of vaccination over the life course. Annu Rev Cell Dev Biol. 2017;33:577\u201399.","journal-title":"Annu Rev Cell Dev Biol"},{"key":"322_CR16","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.cellimm.2015.02.001","volume":"294","author":"TN Jorgensen","year":"2015","unstructured":"Jorgensen TN. Sex disparities in the immune response. Cell Immunol. 2015;294:61\u20132.","journal-title":"Cell Immunol"},{"key":"322_CR17","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S1473-3099(10)70049-9","volume":"10","author":"SL Klein","year":"2010","unstructured":"Klein SL, Jedlicka A, Pekosz A. The Xs and Y of immune responses to viral vaccines. Lancet Infect Dis. 2010;10:338\u201349.","journal-title":"Lancet Infect Dis"},{"key":"322_CR18","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/trstmh\/tru167","volume":"109","author":"SL Klein","year":"2015","unstructured":"Klein SL, Marriott I, Fish EN. Sex-based differences in immune function and responses to vaccination. Trans R Soc Trop Med Hyg. 2015;109:9\u201315.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"322_CR19","first-page":"408","volume":"30","author":"AL Fink","year":"2015","unstructured":"Fink AL, Klein SL. Sex and gender impact immune responses to vaccines among the elderly. Physiology (Bethesda). 2015;30:408\u201316.","journal-title":"Physiology (Bethesda)"},{"key":"322_CR20","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1016\/j.vaccine.2014.01.090","volume":"32","author":"IH Haralambieva","year":"2014","unstructured":"Haralambieva IH, Salk HM, Lambert ND, et al. Associations between race, sex and immune response variations to rubella vaccination in two independent cohorts. Vaccine. 2014;32:1946\u201353.","journal-title":"Vaccine."},{"key":"322_CR21","doi-asserted-by":"crossref","first-page":"62898","DOI":"10.18632\/oncotarget.11704","volume":"7","author":"R Kurupati","year":"2016","unstructured":"Kurupati R, Kossenkov A, Haut L, et al. Race-related differences in antibody responses to the inactivated influenza vaccine are linked to distinct pre-vaccination gene expression profiles in blood. Oncotarget. 2016;7:62898\u2013911.","journal-title":"Oncotarget."},{"key":"322_CR22","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1016\/j.vaccine.2017.04.040","volume":"35","author":"S Moberley","year":"2017","unstructured":"Moberley S, Licciardi PV, Balloch A, et al. Repeat pneumococcal polysaccharide vaccine in Indigenous Australian adults is associated with decreased immune responsiveness. Vaccine. 2017;35:2908\u201315.","journal-title":"Vaccine."},{"key":"322_CR23","first-page":"913","volume":"11","author":"B Rager-Zisman","year":"2004","unstructured":"Rager-Zisman B, Bazarsky E, Skibin A, et al. Differential immune responses to primary measles-mumps-rubella vaccination in Israeli children. Clin Diagn Lab Immunol. 2004;11:913\u20138.","journal-title":"Clin Diagn Lab Immunol"},{"key":"322_CR24","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/j.vaccine.2016.02.036","volume":"34","author":"M Voysey","year":"2016","unstructured":"Voysey M, Barker CI, Snape MD, et al. Sex-dependent immune responses to infant vaccination: an individual participant data meta-analysis of antibody and memory B cells. Vaccine. 2016;34:1657\u201364.","journal-title":"Vaccine."},{"key":"322_CR25","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1097\/INF.0000000000001124","volume":"35","author":"D Muse","year":"2016","unstructured":"Muse D, Christensen S, Bhuyan P, et al. A phase 2, randomized, active-controlled, observer-blinded study to assess the immunogenicity, tolerability and safety of bivalent rLP2086, a meningococcal serogroup B vaccine, coadministered with tetanus, diphtheria and acellular pertussis vaccine and serogroup A, C, Y and W-135 meningococcal conjugate vaccine in healthy US adolescents. Pediatr Infect Dis J. 2016;35:673\u201382.","journal-title":"Pediatr Infect Dis J."},{"key":"322_CR26","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1473-3099(12)70087-7","volume":"12","author":"PC Richmond","year":"2012","unstructured":"Richmond PC, Marshall HS, Nissen MD, et al. Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis. 2012;12:597\u2013607.","journal-title":"Lancet Infect Dis."},{"key":"322_CR27","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1097\/INF.0000000000001072","volume":"35","author":"S Senders","year":"2016","unstructured":"Senders S, Bhuyan P, Jiang Q, et al. Immunogenicity, tolerability, and safety in adolescents of bivalent rLP2086, a meningococcal serogroup B vaccine, coadministered with quadrivalent human papilloma virus vaccine. Pediatr Infect Dis J. 2016;35:548\u201354.","journal-title":"Pediatr Infect Dis J."},{"key":"322_CR28","first-page":"673","volume":"35","author":"T Vesikari","year":"2015","unstructured":"Vesikari T, Ostergaard L, Diez-Domingo J, et al. Meningococcal serogroup B bivalent rLP2086 vaccine elicits broad and robust serum bactericidal responses in healthy adolescents. J Ped Infect Dis Soc. 2015;35:673\u201382.","journal-title":"J Ped Infect Dis Soc."},{"key":"322_CR29","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1093\/jpids\/piv064","volume":"5","author":"T Vesikari","year":"2016","unstructured":"Vesikari T, Wysocki J, Beeslaar J, et al. Immunogenicity, safety, and tolerability of bivalent rLP2086 meningococcal group B vaccine administered concomitantly with diphtheria, tetanus, and acellular pertussis and inactivated poliomyelitis vaccines to healthy adolescents. J Pediatr Infect Dis Soc. 2016;5:180\u20137.","journal-title":"J Pediatr Infect Dis Soc."},{"key":"322_CR30","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1056\/NEJMoa1614474","volume":"377","author":"L Ostergaard","year":"2017","unstructured":"Ostergaard L, Vesikari T, Absalon J, et al. A bivalent meningococcal B vaccine in adolescents and young adults. N Engl J Med. 2017;377:2349\u201362.","journal-title":"N Engl J Med"},{"key":"322_CR31","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1084\/jem.129.6.1307","volume":"129","author":"I Goldschneider","year":"1969","unstructured":"Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med. 1969;129:1307\u201326.","journal-title":"J Exp Med."},{"key":"322_CR32","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/j.vaccine.2005.01.051","volume":"23","author":"R Borrow","year":"2005","unstructured":"Borrow R, Balmer P, Miller E. Meningococcal surrogates of protection\u2014serum bactericidal antibody activity. Vaccine. 2005;23:2222\u20137.","journal-title":"Vaccine."},{"key":"322_CR33","doi-asserted-by":"crossref","first-page":"e00036-18","DOI":"10.1128\/mBio.00036-18","volume":"9","author":"LK McNeil","year":"2018","unstructured":"McNeil LK, Donald RGK, Gribenko A, et al. Predicting the susceptibility of meningococcal serogroup B isolates to bactericidal antibodies elicited by bivalent rLP2086, a novel prophylactic vaccine. MBio. 2018;9:e00036-18.","journal-title":"MBio."},{"key":"322_CR34","doi-asserted-by":"crossref","first-page":"6086","DOI":"10.1016\/j.vaccine.2010.06.083","volume":"28","author":"HQ Jiang","year":"2010","unstructured":"Jiang HQ, Hoiseth SK, Harris SL, et al. Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease. Vaccine. 2010;28:6086\u201393.","journal-title":"Vaccine."},{"key":"322_CR35","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1056\/NEJMoa065368","volume":"356","author":"RB Belshe","year":"2007","unstructured":"Belshe RB, Edwards KM, Vesikari T, et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med. 2007;356:685\u201396.","journal-title":"N Engl J Med"},{"key":"322_CR36","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1056\/NEJMoa0808652","volume":"361","author":"AS Monto","year":"2009","unstructured":"Monto AS, Ohmit SE, Petrie JG, et al. Comparative efficacy of inactivated and live attenuated influenza vaccines. N Engl J Med. 2009;361:1260\u20137.","journal-title":"N Engl J Med"},{"key":"322_CR37","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/cid\/cix766","volume":"66","author":"Y Yang","year":"2018","unstructured":"Yang Y, Meng Y, Halloran ME, Longini IM Jr. Dependency of vaccine efficacy on preexposure and age: a closer look at a tetravalent dengue vaccine. Clin Infect Dis. 2018;66:178\u201384.","journal-title":"Clin Infect Dis"},{"key":"322_CR38","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/cid\/ciu273","volume":"59","author":"J Liko","year":"2014","unstructured":"Liko J, Robison SG, Cieslak PR. Pertussis vaccine performance in an epidemic year\u2014Oregon, 2012. Clin Infect Dis. 2014;59:261\u20133.","journal-title":"Clin Infect Dis"},{"key":"322_CR39","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/0140-6736(92)93086-3","volume":"340","author":"JC de Moraes","year":"1992","unstructured":"de Moraes JC, Perkins BA, Camargo MC, et al. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet. 1992;340:1074\u20138.","journal-title":"Lancet"},{"key":"322_CR40","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jinf.2017.05.001","volume":"75","author":"T Harder","year":"2017","unstructured":"Harder T, Koch J, Wichmann O, Hellenbrand W. Predicted vs observed effectiveness of outer membrane vesicle (OMV) vaccines against meningococcal serogroup B disease: systematic review. J Infect. 2017;75:81\u201394.","journal-title":"J Infect"},{"key":"322_CR41","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1001\/archinternmed.2008.513","volume":"168","author":"RJ Engler","year":"2008","unstructured":"Engler RJ, Nelson MR, Klote MM, et al. Half- vs full-dose trivalent inactivated influenza vaccine (2004\u20132005): age, dose, and sex effects on immune responses. Arch Intern Med. 2008;168:2405\u201314.","journal-title":"Arch Intern Med"},{"key":"322_CR42","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1097\/INF.0b013e318199f901","volume":"28","author":"N Bermal","year":"2009","unstructured":"Bermal N, Szenborn L, Chrobot A, et al. The 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) coadministered with DTPw-HBV\/Hib and poliovirus vaccines: assessment of immunogenicity. Pediatr Infect Dis J. 2009;28:S89\u201396.","journal-title":"Pediatr Infect Dis J."},{"key":"322_CR43","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1097\/INF.0b013e318199f61b","volume":"28","author":"M Knuf","year":"2009","unstructured":"Knuf M, Szenborn L, Moro M, et al. Immunogenicity of routinely used childhood vaccines when coadministered with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV). Pediatr Infect Dis J. 2009;28:S97\u2013108.","journal-title":"Pediatr Infect Dis J."},{"key":"322_CR44","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/1479-5876-8-105","volume":"8","author":"L Mariani","year":"2010","unstructured":"Mariani L, Venuti A. HPV vaccine: an overview of immune response, clinical protection, and new approaches for the future. J Transl Med. 2010;8:105.","journal-title":"J Transl Med."},{"key":"322_CR45","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1007\/s10552-014-0406-2","volume":"25","author":"AC Vidal","year":"2014","unstructured":"Vidal AC, Smith JS, Valea F, et al. HPV genotypes and cervical intraepithelial neoplasia in a multiethnic cohort in the southeastern USA. Cancer Causes Control. 2014;25:1055\u201362.","journal-title":"Cancer Causes Control"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-020-00322-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-020-00322-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-020-00322-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T17:16:32Z","timestamp":1628615792000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-020-00322-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,17]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["322"],"URL":"https:\/\/doi.org\/10.1007\/s40121-020-00322-5","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,17]]},"assertion":[{"value":"8 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}